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Abstract
In this study, we investigated the mRNA and protein
expression of S100A2 and S100A4 in adenocarcinomas
of the stomach and esophagus. Real-time reverse
transcription–polymerase reaction analysis on 72 tu-
mors revealed frequent overexpression of S100A2 and
S100A4 in Barrett’s adenocarcinomas (BAs) (P < .01).
Immunohistochemical analysis on tumor tissue micro-
arrays that contained 187 tumors showed absent to
weak staining for S100A2 in all normal gastric mucosa
samples, whereas normal esophageal mucosa samples
demonstrated moderate to strong nuclear staining.
Contrary to the nuclear expression of S100A2 in normal
esophageal mucosa, two thirds of Barrett’s dysplasia
and BAs that overexpressed S100A2 demonstrated
stronger cytosolic staining than nuclear staining (P <
.001). Overexpression of S100A2 protein was more
frequently seen in well-differentiated tumors than in
others (P = .02). Moderate to strong staining of S100A4
was detected in two thirds of tumors and was fre-
quently observed in the presence of Barrett’s esoph-
agus (P = .02). Similar to S100A2, the expression of
S100A4 was predominantly cytosolic in two thirds of
the tumors (P = .001). There was a significant correla-
tion between S100A4 overexpression and lymph node
metastasis (N2–N4) (P = .027). These results demon-
strate frequent cytosolic overexpression of S100A2 and
S100A4 in BAs. Further studies are ongoing to under-
stand the biological significance of these S100A
proteins in Barrett’s tumorigenesis.
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Introduction
A sharp increase in the incidence of gastroesophageal and
lower esophageal adenocarcinomas has been observed
over the past three decades [1]. Gastroesophageal reflux
disease (GERD) is a major health problem, with a prevalence
of 5% to 7% in the general population [2,3]. Approximately 10%
of patients with chronic GERD develop a metaplastic condition
in which the normal squamous epithelium of the distal esoph-
agus is replaced by a columnar epithelium with goblet cells,
known as Barrett’s esophagus (BE). In the setting of continued
injury as a result of GERD, BE is a serious premalignant
lesion that can ultimately progress from metaplasia to dys-
plasia and, subsequently, to Barrett’s adenocarcinoma (BA),
which affects the lower esophagus and can extend to the
gastroesophageal junction (GEJ) [4–6]. Over the past few
years, BA has shown the fastest rising incidence among
all cancers in the western world [7–12]. These tumors are
characterized by complex molecular alterations and chromo-
somal instability [13,14].
S100 proteins regulate intracellular processes such as cell
growth and motility, cell cycle regulation, transcription, and
differentiation [15]. A unique feature of these proteins is that
individual members are localized in specific cellular compart-
ments from which some are able to relocate on Ca2+ activation,
transducing Ca2+ signal in a temporal and spatial manner by
interacting with different targets specific for each S100 protein
[15–17]. Some members are even secreted from cells exerting
extracellular cytokine-like activities, in part through the surface
receptor RAGE (receptor for advanced glycation end products),
with paracrine effects (e.g., on neurons), promoting their sur-
vival during development or after injury [18]. Many S100 pro-
teins show remarkably cell-specific and tissue-specific
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expression patterns, pointing toward high specification. S100
calcium-binding proteins are of major interest because of
their deregulated expression in human diseases. The cluster
organization of S100 genes is located on human chromo-
some 1q21. We and others have shown frequent rearrange-
ment of 1q21 in several tumors, including adenocarcinomas
of the stomach and esophagus [13–15,18–20].
In this study, we have analyzed the mRNA and protein
expression of S100A2 and S100A4 genes in a large number
of tumors, which included adenocarcinomas of the stomach
and lower esophagus.
Materials and Methods
Tissue Samples
Paraffin-embedded tissue blocks from 187 patients with
lower esophageal, GEJ, gastric (antrum, body, and cardia),
and upper gastrointestinal carcinomas (UGCs) were avail-
able for immunohistochemistry (IHC) analysis. In addition,
six samples with Barrett’s dysplasia were also available.
The average age of patients was 61.7 years (range, 25–
86 years), and the male/female sex ratio was 3.18:1. In
addition, frozen tissue samples from 72 gastric, GEJ, and
lower esophageal tumors, and from 20 normal gastric epi-
thelial samples were dissected for optimal tissue content
(> 70%) and used for mRNA extraction, cDNA synthesis,
and subsequent quantitative real-time reverse transcription–
polymerase chain reaction (RT-PCR) assays. All tissue sam-
ples were collected in accordance with Institutional Review
Board–approved protocols. Tumor grading was performed
according to World Health Organization standards. All cases
were reviewed by our pathologists (S.M.H. and C.A.M.).
Tissue Microarrays
Tissues were stained with hematoxylin and eosin, and
representative regions were selected for inclusion in a tissue
array. Four cores from each case were of a diameter of
0.6 mm and were retrieved from selected regions of donor
blocks and punched to the recipient block using a manual
tissue array instrument (Beecher Instruments, Silver Spring,
MD). Control samples from normal epithelial specimens
were punched in each sample row. A tissue microarray of
normal samples was also constructed. Specimens for con-
trols consisted of 9 normal esophageal squamous samples
and 10 glandular epithelial samples. The resulting tissue
microarray was used for IHC analysis. All tumors and normal
gastric mucosal epithelial tissues were histologically verified.
The adenocarcinomas were collected from the stomach,
GEJ, and lower esophagus; ranged from well-differentiated
to poorly differentiated; and ranged from stages I to IV, with a
mix of intestinal and diffuse-type tumors.
IHC
Tissue microarray sections cut at 5 mm were transferred
to polylysine-coated slides (SuperFrostPlus; Menzel-Gla¨ser,
Braunschweig, Germany) and incubated at 37jC for 2 hours.
Slides were deparaffinized and rehydrated through xylenes
and descending concentrations of ethanol/water. All slides
were quenched for 5 minutes in a 3% hydrogen peroxide so-
lution inmethanol to block endogenous peroxidase. The slides
were immersed in 10mMcitrate buffer (pH6.0) and heated in a
1200-W microwave oven at the highest power setting. Evap-
orated liquid was replenished at 5 minutes and then heated
on high for an additional 5 minutes. The slides were left in
the buffer for an additional 10 minutes before removal. The
antibodies used were mouse monoclonal antibody to S100A2
(DAK-S100A2/1; DAKO, Glostrup, Denmark) and rabbit poly-
clonal antibody to S100A4 (S100A4 Ab-8; Neomarkers, Inc.,
Fremont, CA). Immunostaining was performed by a Ventana
ES automated slide stainer (Ventana Medical Systems, Inc.,
Tucson, AZ) using diluted antibody solution (1:50 for S100A2;
1:200 for S100A4) during a 32-minute incubation at 37jC.
Antibody binding was visualized using the streptavidin–
peroxidase technique (Ventana iVIEW DAB detection kit;
Ventana Medical Systems, Inc.) followed by incubation with
3,3V-diaminobenzidine tetrahydrochloride. The slides were
counterstained with hematoxylin and mounted with DEPEX.
Negative controls consisted of identically treated histologic
sections, except for the addition of primary antibody. All stains
were evaluated independently by two authors who were
blinded to the clinicopathological features associated with
the specimen. Cases with discordant results were reviewed
simultaneously for consensus opinion. For all antibodies used
in this study, a case was considered negative on tumor tissue
microarray only if all four cores were negative. Cores with no
evidence of nuclear or cytosolic staining, or those with evi-
dence of only rare scattered positive cells (< 3%) were
recorded as negative. Immunohistochemical results were
evaluated for the intensity and frequency of staining of nuclear
and cytosolic components, and for the intensity and frequency
of staining as a whole. The intensity of staining was graded
as 0 = negative, 1 = weak, 2 = moderate, and 3 = strong.
The frequency was graded from 0 to 4 by the percentage of
positive cells, as follows: grade 0, < 3%; grade 1, 3% to 25%;
grade 2, 25% to 50%; grade 3, 50% to 75%; grade 4, > 75%.
The index score is the product of the intensity and frequency
grades, which was then binned into a four-point scale: index
score 0 = product 0; index score 1 = products 1 and 2; index
score 2 = products 3 and 4; index score 3 = products 6 to 12.
Index score 2 or 3 was determined as the overexpression of
proteins. Immunohistochemically stained tumor tissue micro-
arrays were analyzed under a digital microscope (Nikon
Instech Co., Ltd, Tokyo, Japan).
Quantitative Real-Time RT-PCR
mRNA was isolated using the RNeasy kit (Qiagen Gmbh,
Hilden, Germany), then single-stranded cDNA was sub-
sequently synthesized using the Advantage RT-for-PCR Kit
(Clontech, Palo Alto, CA). Quantitative real-time RT-PCR
was performed using 72 frozen tissue samples of lower
esophageal, GEJ, and gastric adenocarcinoma samples,
and 20 normal gastric mucosal samples, using an iCycler
(Bio-Rad, Hercules, CA). Threshold cycle number was de-
termined using iCycler software (version 3.0; Bio-Rad), as
described earlier [21]. The primers used for real-time
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RT-PCR were obtained from GeneLink (Hawthorne, NY). The
sequences for the S100A2 primers are 5V GAACTTCTGCA-
CAAGGAGCTG 3V (forward) and 5V GACAGTGATGAGTGC-
CAGGA 3V (reverse). The sequences for the S100A4 primers
are 5V CCACAAGTACTCGGGCAAAG 3V (forward) and 5V
GTCCCTGTTGCTGTCCAAGT 3V (reverse). Reactions were
performed in duplicate, and threshold cycle numbers were
averaged. A single melt curve peak was observed for each
sample used in data analysis, thus confirming the purity and
specificity of all amplified products. The results for S100A2
and S100A4 were normalized to HPRT1, which had minimal
variation in all normal and neoplastic gastric samples tested.
The fold expression in tumors (compared with that in normal
samples) was calculated and normalized with HPRT1 values
according to the formula: 2(Rt  Et)/2(Rn  En), as described
elsewhere [21], where Rt is the threshold cycle number for
the reference gene observed in the tumor, Et is the threshold
cycle number for the experimental gene observed in the tumor,
Rn is the threshold cycle number for the reference gene
observed in the normal sample, and En is the threshold cycle
number for the experimental gene observed in the normal
sample. Rn and En values were averaged from the 20 normal
mucosa samples. Each tumor sample was compared to the
20 normal samples. The relative fold expression in tumors
with a standard error of themean (±SEM) is shown in Figure 1.
Statistical Analysis
Frequencies and other summary statistics were calcu-
lated. Chi-square tests of association were performed to
examine potential relationships between expression levels
through PCR and IHC, and between parameters of demo-
graphic, clinical, or pathological nature.
Results
Overexpression of S100A2 and S100A4 mRNA in Tumors
Versus Normal Mucosa
Quantitative real-time PCR analysis revealed mRNA
overexpression of S100A2 in 54% (39 of 72) and overexpres-
sion of S100A4 in 28% of all tumors (Figure 1). The over-
expression of S100A2 and S100A4 was more frequently
seen in BAs of the GEJ and lower esophagus than in stom-
ach tumors (74% vs 41%, P = .01; and 39% vs 19%, P = .069,
respectively). Interestingly, most of the tumors that over-
expressed S100A4 also overexpressed S100A2 (16 of 19,
84%) (P < .01) (Figure 1).
Overexpression of S100A2 and S100A4 Proteins in Tumors
The IHC for S100A2 showed moderate to strong immuno-
staining in normal esophageal squamous epithelium
samples. S100A2 immunoreactivity was observed homog-
enously in all cells throughout the epithelium, including basal
layer cells, and staining intensity was stronger in nuclei. The
normal glandular epithelium of the stomach had absent to
low immunostaining for S100A2, and the expression was
mainly in the deeper—not in the superficial—glandular epi-
thelium. The IHC indicated the absence of S100A4 protein
expression in all normal squamous or glandular epithelia
(Figures 2 and 3).
Six of seven Barrett’s dysplasia samples showed mod-
erate to strong immunoreactivity for S100A2, with a predom-
inant cytosolic expression pattern similar to that seen in BAs
(Figure 2, C and D). Moderate to strong immunostaining
of S100A2 protein was observed in 122 of 187 (65%) of
UGCs (Figure 2). There was no statistically significant rela-
tionship between the immunostaining of S100A2 and clinico-
pathological variables, including gender, tumor location,
presence of BE, histologic grade, involvement of lymph node,
or tumor stage (Table 1). Together, these results may indicate
that expression of S100A2 may be an important and early
step in UGC tumorigenesis. Interestingly, there was a trans-
location of S100A2 expression from a predominantly nuclear
Figure 1. High levels of (A) S100A2 and (B) S100A4 mRNA expression in
esophageal, GEJ, and gastric adenocarcinomas. Quantitative real-time RT-
PCR analysis was performed on 72 lower esophageal, GEJ, and gastric
adenocarcinoma samples using iCycler (Bio-Rad), in comparison with 20
normal glandular mucosa samples. The horizontal axis shows sample
numbers, whereas the fold expression in tumor samples compared with that
in normal samples is shown in the vertical axis. The fold expression was
calculated according to the formula: 2(Rt  Et)/2(Rn  En). Each bar represents one
tumor sample. Downregulation is shown as negative fold expression values.
The displayed mean fold expression for each tumor sample is calculated in
comparison with expression in 20 normal samples. The expression of S100A2
and S100A4 was normalized to the expression of HPRT1, which showed
minimal variation in all normal and neoplastic samples tested.
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staining in normal esophageal tissues to a strong cytosolic
staining in the majority of adenocarcinomas. Although all
normal esophageal mucosae revealed a nuclear predomi-
nance of S100A2 protein expression (Figure 2B), only 11%
of BAs showed nuclear predominance. Almost all tumors
overexpressing S100A2 (89%) showed equivalent cyto-
solic and nuclear expressions or cytosolic predominance.
Predominant cytosolic expression was observed in 65%
of BAs that showed S100A2 overexpression (P < .01)
(Figure 2). The S100A4 protein was not expressed in normal
squamous or columnar epithelia, except for focal weak
nuclear and/or cytosolic staining of some scattered stromal
Figure 2. Immunohistochemical analysis for the S100A2 protein. (A) Normal gastric glandular epithelium shows no immunoreactivity. (B) Normal esophageal
squamous epithelium shows moderate staining (score 2) with predominant nuclear localization (inset: original magnification, 400) with a stronger intensity in basal
epithelial layers. (C and D) Barrett’s dysplasia of the lower esophagus demonstrates moderate immunoreactivity (score 2) with predominant cytosolic localization
(C: original magnification, 100; D: original magnification, 200). (E–H) BA of the GEJ (intestinal type; E and F) and lower esophagus (diffuse type; G and H) (E
and G: original magnification, 100; F and H: original magnification, 200) showing strong cytosolic S100A2 positivity (score 3).
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and inflammatory cells (Figure 3). Unlike normal mucosa
samples, UGCs demonstrated moderate to strong staining
in 67% (124 of 185) of tumors. The overexpression of
S100A4 was more frequently observed in BAs than in
gastric (antrum, body, and cardia) adenocarcinomas (P =
.013) (Table 1 and Figure 3).
Discussion
Several pathological disorders, including cancer, are linked to
altered Ca2+ homeostasis and might involve multifunctional
S100 proteins, which are expressed in a cell-specific and
tissue-specific manner. The role of calcium-binding proteins
in carcinogenesis has drawn a complex picture showing
Figure 3. Immunohistochemical analysis for the S100A4 protein. (A and B) Immunostaining for S100A4 shows no immunoreactivity in normal esophageal
squamous epithelium (A: original magnification, 100; B: original magnification, 200). (C and D) Normal gastric glandular epithelium demonstrates no stain-
ing except for scattered inflammatory cells (A: original magnification, 100; B: original magnification, 200). (E–H) BAs of the GEJ (E: original magnification,
100; F: original magnification, 400) and lower esophagus (G and H: original magnification, 100) show moderate to strong immunoreactivity with cyto-
solic predominance.
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downregulation or overexpression in different tumors [15,
17,22–24]. The biologic function of several S100A proteins
in carcinogenesis has not been fully elucidated to date. In
this study, we have shown frequent mRNA and protein over-
expression of S100A2 and S100A4 in BAs of the GEJ and
lower esophagus. The mechanisms by which S100 proteins
act as tumor promoters or suppressors differ widely. In
particular, the role of S100A2 in carcinogenesis draws a
more complex picture. S100A2 was originally described as
a tumor suppressor because reduced levels of S100A2 were
detected in squamous cell lung carcinoma and breast cancer
[25–27]. However, several studies have shown that S100A2
is highly expressed in tumors such as ovarian cancer, esoph-
ageal squamous cell carcinoma, and non–small cell lung
cancer [22,23,28,29]. We have detected S100A2 over-
expression at both mRNA and protein levels in lower esoph-
ageal, GEJ, and gastric adenocarcinomas. A recent study
has shown that S100A2 is a novel downstream mediator of
DeltaNp63 oncogenic activity [30]. However, in most cases,
the function of S100 proteins in cancer cells is still unknown,
and specific expression patterns of these proteins can be
used as a valuable prognostic tool. We have found over-
expression of the S100A2 protein in almost all samples of
Barrett’s dysplasia. We could not observe a trend for lymph
node involvement in adenocarcinomas overexpressing
S100A2. A study of S100A2-overexpressing esophageal
squamous cell carcinoma showed a similar trend toward
preferentially developing lymph nodemetastases and distant
metastases (P = .111 and .178, respectively) [23]. Similarly,
immunohistochemical analyses of 94 primary lung adeno-
carcinomas showed that positive S100A2 expression was
significantly associated with lymphatic invasion (P = .0233)
[31]. The S100A2 expression was predominantly cytosolic in
Barrett’s dysplasia and adenocarcinoma. In contrast, we
noted a predominant nuclear localization of the S100A2
protein in normal squamous epithelial cells. This finding is
also supported by other immunolocalization studies showing
that the S100A2 protein is preferably located in the nucleus in
normal tissues [17,32,33]. A similar relocation of S100A2
from the nucleus to the cytoplasm was observed in cultured
normal human keratinocytes when cells were treated with
H2O2 or exposed to an ionophore-dependent increase in
Table 1. Summary of the IHC Analysis of S100A2 and S100A4 in 187 Tumors.
S100A2 S100A4
Normal Overexpression P Normal Overexpression P
Gender (NA = 5)
Female (n = 46) 14 32 .67 21 25 .020
Male (n = 136) 46 90 37 99
Total 60 122 58 124
BE (NA = 58)
No (n = 61) 26 35 .17 28 33 .013
Yes (n = 68) 21 47 17 51
Total 47 82 45 84
Site (NA = 6)
Stomach (n = 48) 20 28 .096 19 29 .16
GEJ and esophagus (n = 133) 38 95 38 95
Total 58 123 57 124
Histology (NA = 18)
Diffuse (n = 62) 16 46 .38 14 48 .51
Intestinal (n = 99) 32 67 27 72
Other (n = 8) 2 6 4 4
Total 50 119 45 124
Stage (NA = 35)
I and II (n = 70) 19 51 .12 20 50 .37
III and IV (n = 82) 32 50 29 53
Total 51 101 49 103
Node (NA = 21)
N0 (n = 72) 24 48 .96 23 49 .027
N1 (n = 42) 16 26 21 21
N2–N4 (n = 52) 15 37 11 41
Total 55 111 55 111
Grade (NA = 34)
Well differentiated (n = 11) 0 11 .02 3 8 .69
Moderately differentiated (n = 48) 19 29 17 31
Poorly differentiated (n = 94) 30 64 27 67
Total 49 104 47 106
NA = not available.
P V .05 was considered significant.
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intracellular calcium [34]. The interaction between nuclear
S100A2 and p53 has been recently reported, where over-
expression of S100A2 increases the transcriptional activity
of p53 [35]. The observed translocation of S100A2 from
the nucleus to the cytoplasm in Barrett’s dysplasia and
adenocarcinomas may indicate a change in the level of the
S100A2-mediated transcription activity of p53 and suggest
an oncogenic potential of cytoplasmic S100A2. Therefore,
the change of localization of the S100A2 protein may be
a reflection of a change in function and biological outcome
that needs to be investigated further.
We found that overexpression of the S100A4 protein was
significantly related to GEJ and lower esophageal BAs. IHC
staining for S100A4 was absent in both normal esophageal
squamous epithelium and normal gastric columnar epi-
thelium. We also observed a predominant cytosolic localiza-
tion of the S100A4 protein in GEJ and lower esophageal
adenocarcinomas. Interestingly, there was a strong statistical
correlation (P = .03) between overexpression of S100A4
protein and advanced lymph node metastasis (N2–N4).
These tumors, compared with other histologic subtypes,
are characterized by poor outcome. A number of clinical
studies showed a correlation between S100A4 expression
andworse prognostic outcome in a variety of human cancers,
confirming the importance of S100A4 in cancer progression
[16,29,36–40]. Overexpression of S100A4 correlates with
lymph node metastasis in colorectal cancers [36]. In breast
cancer, S100A4 expression is a potential predictor of metas-
tasis and survival in early-stage tumors [35]. As a typical
member of the S100 protein family, S100A4 exhibits dual
extracellular and intracellular functions. The intracellular
S100A4 protein could interfere with vital cellular functions
such as cell motility, invasion, cell division, and survival
[41,42]. Interestingly, a strong inverse relationship was
found between S100A4 and p53 expression [31]. Despite
the relationship between the expression of S100A4 and the
poor outcome, the actual mechanism of S100A4’s tumor-
promoting function remains poorly investigated [18].
In summary, we have demonstrated high mRNA and
protein expression levels of S100A2 and S100A4 in BAs.
Our results suggest that the cytosolic localization of S100A
proteins in adenocarcinomas may reflect a change of Ca2+
homeostasis that occurs in connection with BE and tumor
differentiation. The frequent overexpression of these pro-
teins, together with a change in their cellular localization,
indicates that these proteins may play a critical role during
Barrett’s tumorigenesis.
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